Delayed musculoskeletal symptoms after breast radiotherapy can reflect osteoradionecrosis rather than recurrence, thus ...
In this phase 3 trial, researchers aimed to study the efficacy of tumor bed boost and moderately hypofractionated whole breast irradiation in patients with non-low-risk DCIS.
The authors conclude that cryoablation represents a promising, minimally invasive treatment option for carefully selected ...
MELBOURNE, Australia, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel treatments for chronic ...
- EMA provided overall agreement with the proposed Phase 3 clinical trial of VCN-01 in combination with gemcitabine/nab-paclitaxel for the first-line treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback